Angle PLC
LSE:AGL

Watchlist Manager
Angle PLC Logo
Angle PLC
LSE:AGL
Watchlist
Price: 8 GBX 3.23%
Market Cap: 25.8m GBX
Have any thoughts about
Angle PLC?
Write Note

Intrinsic Value

AGL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one AGL stock under the Base Case scenario is 23.11 GBX. Compared to the current market price of 8 GBX, Angle PLC is Undervalued by 65%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AGL Intrinsic Value
23.11 GBX
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Angle PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AGL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AGL?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Health Care Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Angle PLC

Provide an overview of the primary business activities
of Angle PLC.

What unique competitive advantages
does Angle PLC hold over its rivals?

What risks and challenges
does Angle PLC face in the near future?

Summarize the latest earnings call
of Angle PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Angle PLC.

Provide P/S
for Angle PLC.

Provide P/E
for Angle PLC.

Provide P/OCF
for Angle PLC.

Provide P/FCFE
for Angle PLC.

Provide P/B
for Angle PLC.

Provide EV/S
for Angle PLC.

Provide EV/GP
for Angle PLC.

Provide EV/EBITDA
for Angle PLC.

Provide EV/EBIT
for Angle PLC.

Provide EV/OCF
for Angle PLC.

Provide EV/FCFF
for Angle PLC.

Provide EV/IC
for Angle PLC.

Show me price targets
for Angle PLC made by professional analysts.

What are the Revenue projections
for Angle PLC?

How accurate were the past Revenue estimates
for Angle PLC?

What are the Net Income projections
for Angle PLC?

How accurate were the past Net Income estimates
for Angle PLC?

What are the EPS projections
for Angle PLC?

How accurate were the past EPS estimates
for Angle PLC?

What are the EBIT projections
for Angle PLC?

How accurate were the past EBIT estimates
for Angle PLC?

Compare the revenue forecasts
for Angle PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Angle PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Angle PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Angle PLC compared to its peers.

Compare the P/E ratios
of Angle PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Angle PLC with its peers.

Analyze the financial leverage
of Angle PLC compared to its main competitors.

Show all profitability ratios
for Angle PLC.

Provide ROE
for Angle PLC.

Provide ROA
for Angle PLC.

Provide ROIC
for Angle PLC.

Provide ROCE
for Angle PLC.

Provide Gross Margin
for Angle PLC.

Provide Operating Margin
for Angle PLC.

Provide Net Margin
for Angle PLC.

Provide FCF Margin
for Angle PLC.

Show all solvency ratios
for Angle PLC.

Provide D/E Ratio
for Angle PLC.

Provide D/A Ratio
for Angle PLC.

Provide Interest Coverage Ratio
for Angle PLC.

Provide Altman Z-Score Ratio
for Angle PLC.

Provide Quick Ratio
for Angle PLC.

Provide Current Ratio
for Angle PLC.

Provide Cash Ratio
for Angle PLC.

What is the historical Revenue growth
over the last 5 years for Angle PLC?

What is the historical Net Income growth
over the last 5 years for Angle PLC?

What is the current Free Cash Flow
of Angle PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Angle PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Angle PLC

Current Assets 23.6m
Cash & Short-Term Investments 17.9m
Receivables 4m
Other Current Assets 1.8m
Non-Current Assets 9.4m
PP&E 6.7m
Intangibles 2.7m
Current Liabilities 4.6m
Accounts Payable 3.4m
Other Current Liabilities 1.1m
Non-Current Liabilities 3.9m
Long-Term Debt 3.5m
Other Non-Current Liabilities 413k
Efficiency

Earnings Waterfall
Angle PLC

Revenue
2m GBP
Cost of Revenue
-626k GBP
Gross Profit
1.4m GBP
Operating Expenses
-20.8m GBP
Operating Income
-19.4m GBP
Other Expenses
1.4m GBP
Net Income
-18m GBP

Free Cash Flow Analysis
Angle PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

ANGLE is refocusing on large pharmaceutical partnerships, having secured three contracts in the first half of 2024, including one with Eisai and two with AstraZeneca. Despite a disappointing revenue of GBP 1 million and a reduction in product sales, they foresee potential revenue growth of GBP 3 million to GBP 3.7 million for the full year, with expectations for H2 revenues to double. The company anticipates cash flow positivity by 2026 as large pharma contracts cover development costs, enhancing profitability. Recent breakthroughs in DNA technology and a strong cash position of GBP 17.9 million support this new direction.

What is Earnings Call?
Fundamental Scores

AGL Profitability Score
Profitability Due Diligence

Angle PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROE is Increasing
28/100
Profitability
Score

Angle PLC's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

AGL Solvency Score
Solvency Due Diligence

Angle PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
54/100
Solvency
Score

Angle PLC's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGL Price Targets Summary
Angle PLC

There are no price targets for AGL.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AGL?

Click here to dive deeper.

Dividends

Angle PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AGL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Angle PLC Logo
Angle PLC

Country

United Kingdom

Industry

Health Care

Market Cap

25.8m GBP

Dividend Yield

0%

Description

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

Contact

SURREY
Guildford
The Surrey Research Park, 10 Nugent Road
+441483343434.0
www.angleplc.com

IPO

2004-03-17

Employees

102

Officers

Founder, CEO & Executive Director
Mr. Andrew David William Newland ACA, Meng
CFO, Finance Director, Company Secretary & Executive Director
Mr. Ian Francis Griffiths ACA, BA
Director of Operations & Regulatory Affairs
Mr. Martin Cooke
Chief Scientific Officer
Dr. Karen Miller Ph.D.
Head of Investor Relations
Mr. Andrew John Holder
Head of R&D and Senior Director
Ms. Anne-Sophie Pailhes-Jimenez
Show More
Chief Commercial Officer
Mr. Brett Swansiger
Show Less

See Also

Discover More
What is the Intrinsic Value of one AGL stock?

The intrinsic value of one AGL stock under the Base Case scenario is 23.11 GBX.

Is AGL stock undervalued or overvalued?

Compared to the current market price of 8 GBX, Angle PLC is Undervalued by 65%.

Back to Top